SCD and neoplasm: In metabolic targeted therapy, targeting key metabolic enzymes (such as FASN, SCD1, and ACC) and lipid and glucose metabolic pathways can inhibit tumor growth and be combined with immune checkpoint inhibitors and targeted therapy to form personalized treatment plans.